564 Shares in McKesson Corporation (NYSE:MCK) Bought by Bridgewater Advisors Inc.

Bridgewater Advisors Inc. purchased a new stake in shares of McKesson Corporation (NYSE:MCK - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 564 shares of the company's stock, valued at approximately $399,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Capital A Wealth Management LLC bought a new stake in shares of McKesson during the 4th quarter valued at about $26,000. Millstone Evans Group LLC bought a new stake in shares of McKesson during the 4th quarter valued at about $28,000. Graney & King LLC bought a new stake in shares of McKesson during the 4th quarter valued at about $38,000. CoreFirst Bank & Trust bought a new stake in shares of McKesson during the 4th quarter valued at about $67,000. Finally, Cornerstone Planning Group LLC grew its stake in shares of McKesson by 1,840.0% during the 1st quarter. Cornerstone Planning Group LLC now owns 97 shares of the company's stock valued at $67,000 after purchasing an additional 92 shares during the period. 85.07% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, EVP Leann B. Smith sold 1,248 shares of the stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $717.30, for a total transaction of $895,190.40. Following the transaction, the executive vice president owned 2,621 shares of the company's stock, valued at approximately $1,880,043.30. This represents a 32.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Thomas L. Rodgers sold 2,891 shares of the stock in a transaction on Friday, May 30th. The stock was sold at an average price of $712.18, for a total value of $2,058,912.38. Following the transaction, the executive vice president directly owned 2,544 shares in the company, valued at $1,811,785.92. The trade was a 53.19% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 52,488 shares of company stock worth $37,242,862 over the last ninety days. Corporate insiders own 0.08% of the company's stock.

McKesson Trading Down 0.1%

Shares of NYSE MCK traded down $0.44 during trading hours on Friday, hitting $709.84. 496,474 shares of the company traded hands, compared to its average volume of 921,244. The stock has a market capitalization of $88.81 billion, a price-to-earnings ratio of 27.48, a price-to-earnings-growth ratio of 1.42 and a beta of 0.48. The company's 50 day moving average price is $716.44 and its 200 day moving average price is $667.56. McKesson Corporation has a 12 month low of $464.42 and a 12 month high of $737.89.

McKesson (NYSE:MCK - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $10.12 EPS for the quarter, beating the consensus estimate of $9.83 by $0.29. The company had revenue of $90.82 billion for the quarter, compared to the consensus estimate of $94 billion. McKesson had a negative return on equity of 201.12% and a net margin of 0.92%. McKesson's quarterly revenue was up 18.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $6.18 EPS. Equities analysts anticipate that McKesson Corporation will post 32.77 EPS for the current year.

McKesson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, July 1st. Shareholders of record on Monday, June 2nd were given a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 0.40%. The ex-dividend date of this dividend was Monday, June 2nd. McKesson's dividend payout ratio (DPR) is presently 10.99%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on MCK shares. UBS Group boosted their price target on McKesson from $708.00 to $805.00 and gave the company a "buy" rating in a research note on Tuesday, April 29th. Wall Street Zen cut McKesson from a "strong-buy" rating to a "buy" rating in a research report on Sunday, July 13th. Cfra Research cut McKesson from a "moderate buy" rating to a "hold" rating in a research report on Friday, April 4th. Morgan Stanley reaffirmed an "overweight" rating and set a $810.00 price objective (up from $770.00) on shares of McKesson in a research report on Wednesday. Finally, Mizuho boosted their price target on McKesson from $630.00 to $690.00 and gave the stock a "neutral" rating in a report on Thursday, April 3rd. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, McKesson presently has an average rating of "Moderate Buy" and an average price target of $710.17.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.